Dr. Robert Wise, M.D.
Pulmonology (Pulmonary Disease Physician)
601 N Caroline St
Baltimore, MD 21287
Who else practices at this address →
Baltimore city includes primary care (36% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- Harvard Medical School (1971)
- Years since graduation
- 55
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 1,605
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1971Medical school: Harvard Medical School
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pulmonary Disease Physician primary
MD license D20775
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Johns Hopkins Hospital, the Baltimore, MD
- Johns Hopkins Bayview Medical Center Baltimore, MD
Medical groups
- Johns Hopkins University (2,909 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 1,605
- Services billed
- 4,857
- Patients’ average age
- 71
| Service | Times | Patients |
|---|---|---|
| Test to examine how well the lungs exchange gases | 1,278 | 1,123 |
| Test to measure expiratory airflow and volume | 1,164 | 979 |
| Test to determine lung volumes using gas dilution or washout | 1,046 | 929 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 365 | 360 |
| Test to determine lung volumes using sensors | 142 | 141 |
| Test for exercise-induced lung stress | 69 | 69 |
| Established patient office or other outpatient visit, 30-39 minutes | 58 | 40 |
| Established patient office or other outpatient visit, 40-54 minutes | 21 | 18 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Albuterol Sulfate Hfa (albuterol sulfate) Other prescribers in Baltimore, MD | 74 |
| Anoro Ellipta (umeclidinium brm/vilanterol tr) Other prescribers in Baltimore, MD | 36 |
| Trelegy Ellipta (fluticasone/umeclidin/vilanter) Other prescribers in Baltimore, MD | 35 |
| Azithromycin Other prescribers in Baltimore, MD | 29 |
| Stiolto Respimat (tiotropium br/olodaterol hcl) Other prescribers in Baltimore, MD | 26 |
| Prednisone Other prescribers in Baltimore, MD | 24 |
| Arnuity Ellipta (fluticasone furoate) Other prescribers in Baltimore, MD | 12 |
| Montelukast Sodium Other prescribers in Baltimore, MD | 12 |
| Pregabalin Other prescribers in Baltimore, MD | 12 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 8 companies reported 17 payments worth $99,400 in total to this clinician.
| AstraZeneca UK Limited | $37,525 |
|---|---|
| AstraZeneca Pharmaceuticals LP | $28,500 |
| Chiesi USA, Inc. | $14,700 |
| E.r. Squibb & Sons, L.l.c. | $6,750 |
| AbbVie Inc. | $4,200 |
| Pulmonx Corporation | $3,800 |
| GlaxoSmithKline, LLC. | $2,925 |
| Merck Sharp & Dohme LLC | $1,000 |
| Consulting Fee | $99,400 |
|---|
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP Aug 4, 2025 | Consulting Fee | $28,500 |
| AstraZeneca UK Limited Dec 11, 2025 | Consulting Fee BREZTRI · Respiratory | $20,500 |
| AstraZeneca UK Limited Jul 10, 2025 | Consulting Fee BREZTRI · Respiratory | $15,525 |
| E.r. Squibb & Sons, L.l.c. May 13, 2025 | Consulting Fee | $6,750 |
| Chiesi USA, Inc. Dec 11, 2025 | Consulting Fee | $4,800 |
| Chiesi USA, Inc. Dec 18, 2025 | Consulting Fee | $4,800 |
| AbbVie Inc. Jan 2, 2025 | Consulting Fee | $4,200 |
| Chiesi USA, Inc. Sep 25, 2025 | Consulting Fee | $3,300 |
| GlaxoSmithKline, LLC. Apr 9, 2025 | Consulting Fee | $2,925 |
| Chiesi USA, Inc. Aug 7, 2025 | Consulting Fee | $1,800 |
All 17 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Chiesi USA, Inc. Dec 18, 2025 | Consulting Fee | $4,800 |
| AstraZeneca UK Limited Dec 11, 2025 | Consulting Fee BREZTRI · Respiratory | $20,500 |
| Chiesi USA, Inc. Dec 11, 2025 | Consulting Fee | $4,800 |
| Chiesi USA, Inc. Sep 25, 2025 | Consulting Fee | $3,300 |
| Pulmonx Corporation Sep 10, 2025 | Consulting Fee ZEPHYR ENDOBRONCHIAL VALVE; PULMONX CHARTIS TABLET CONSOLE; CHARTIS CATHETER · PULMONOLOGY | $900 |
| Pulmonx Corporation Sep 10, 2025 | Consulting Fee ZEPHYR ENDOBRONCHIAL VALVE; PULMONX CHARTIS TABLET CONSOLE; CHARTIS CATHETER · PULMONOLOGY | $900 |
| Merck Sharp & Dohme LLC Sep 3, 2025 | Consulting FeeCompany’s descriptionProvided as part of a research engagement. | $250 |
| Chiesi USA, Inc. Aug 7, 2025 | Consulting Fee | $1,800 |
| AstraZeneca Pharmaceuticals LP Aug 4, 2025 | Consulting Fee | $28,500 |
| AstraZeneca UK Limited Jul 10, 2025 | Consulting Fee BREZTRI · Respiratory | $15,525 |
| Merck Sharp & Dohme LLC May 21, 2025 | Consulting FeeCompany’s descriptionProvided as part of a research engagement. | $750 |
| AstraZeneca UK Limited May 19, 2025 | Consulting Fee FASENRA · Respiratory | $1,500 |
| E.r. Squibb & Sons, L.l.c. May 13, 2025 | Consulting Fee | $6,750 |
| GlaxoSmithKline, LLC. Apr 9, 2025 | Consulting Fee | $2,925 |
| Pulmonx Corporation Jan 15, 2025 | Consulting Fee ZEPHYR ENDOBRONCHIAL VALVE · PULMONOLOGY | $1,000 |
| Pulmonx Corporation Jan 15, 2025 | Consulting Fee ZEPHYR ENDOBRONCHIAL VALVE · PULMONOLOGY | $1,000 |
| AbbVie Inc. Jan 2, 2025 | Consulting Fee | $4,200 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $106,238 in research payments for these studies, mostly to the institutions running them.
- Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD)
Sanofi US Services Inc. · Completed · NCT04751487 - A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler MDI Rel…
AstraZeneca Pharmaceuticals LP
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.